Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: SUMMARY: Juvenile myasthenia gravis, like its adult-onset counterpart, is a heterogeneous disease. Clinical presentation is influenced by antibody status, ethnicity and age of onset. Treatment is very effective, but guidelines and controlled trials are needed.The risk for neonatal myasthenia gravis appears to be markedly influenced by maternal antibody subclass and antigen specificity. Adequate treatment in mothers can reduce both frequency and severity of neonatal disease.
|
Authors | Amelia Evoli |
Journal | Current opinion in neurology
(Curr Opin Neurol)
Vol. 23
Issue 5
Pg. 536-40
(Oct 2010)
ISSN: 1473-6551 [Electronic] England |
PMID | 20581680
(Publication Type: Journal Article, Review)
|
Chemical References |
- Autoantibodies
- Receptors, Cholinergic
- MUSK protein, human
- Receptor Protein-Tyrosine Kinases
|
Topics |
- Age of Onset
- Autoantibodies
(immunology)
- Humans
- Myasthenia Gravis
(classification, epidemiology, genetics, physiopathology)
- Myasthenia Gravis, Neonatal
(genetics, physiopathology)
- Receptor Protein-Tyrosine Kinases
(immunology)
- Receptors, Cholinergic
(immunology)
|